176
Participants
Start Date
May 1, 2025
Primary Completion Date
November 30, 2030
Study Completion Date
November 30, 2031
Elranatamab
"Each injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible.~Each participant may receive study intervention for a maximum of 24 cycles."
Daratumumab
1800 mg will be administrated every cycles
Lenalidomide
Daily administarted during 21 days, at each cycle
CHU Angers, Angers
CH Côte Basque, Bayonne
CHU Besançon, Besançon
CHU Caen, Caen
Hôpital d'Instruction des Armées Percy, Clamart
CHU Clermont- Ferrand - Hôpital ESTAING, Clermont-Ferrand
Hôpital Henri Mondor, Créteil
CHRU Dijon, Dijon
Institut de cancérologie de Bourgogne, Dijon
Hôpital Annecy Genevois, Épagny
CHD Vendée, La Roche-sur-Yon
CH Le Mans - Centre de cancérologie de la Sarthe, Le Mans
CH de Libourne, Libourne
CHU Limoges, Limoges
Groupement Hospitalier Bretagne Sud, Lorient
Centre Léon BERARD, Lyon
IPC Marseille, Marseille
CHRU Nancy, Nancy
CHU Nantes, Nantes
CHU de Nice - Hôpital l'Archet 1, Nice
CHU de Nîmes - Institut de Cancérologie du Gard, Nîmes
Hopital St Louis, Paris
Hôpital Cochin, Paris
Hôpital Necker, Paris
Hôpital St Antoine, Paris
CH Saint-Jean, Perpignan
CHRU - Hôpital du Haut Lévêque, Pessac
CH Périgueux, Périgueux
CHU de Poitiers, Poitiers
CH Cornouaille Quimper, Quimper
CH de Saint Nazaire, Saint-Nazaire
ICANS, Strasbourg
CH Tarbes-Lourdes, Tarbes
CHU Toulouse, Toulouse
CHRU Bretonneau, Tours
CH Bretagne Atlantique, Vannes
Nantes University Hospital
OTHER